1. A method of treating psoriasis comprising the following steps: a) administering an anti-IL-17 antibody during an induction regimen, wherein the induction regimen includes a loading regimen, where the loading regimen includes administering five doses of about 150 mg to about 300 mg of an anti-IL-17 antibody each of the five doses being administered weekly starting from week zero； and b) subsequent administration of an anti-IL antibody during a maintenance schedule wherein said anti-IL-17 antibody binds an epitope of an IL-17 homodimer having two chains of the mature IL-17 protein, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124 , Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, where the anti-IL-17 antibody has K100-200 pM, and where the anti-IL-17 antibody has a half-life in vivo 23-30 days. 2. The method of claim 1, wherein the loading regimen comprises administering five doses of about 150 mg or about 300 mg of an anti-IL-17.3 antibody. The method according to claim 2, where five doses of about 150 mg are administered to the patient if his weight is less than 90 kg, and five doses of about 300 mg are administered to the patient if his weight is greater than or equal to 90 kg. The method of claim 3, wherein the induction regimen further comprises administering to the patient about 150 mg to about 300 mg of an anti-IL-17 antibody for the eighth week. The method of claim 1, wherein the maintenance regimen comprises treating a patient of about 150 mg to about 300 mg of an anti-IL-17 antibody monthly. A method according to any one of claims 1 to 5, wherein the maintenance regimen comprises treating a patient with at least one dose of about 150 mg to about 300 mg of an anti-IL-17 antibody at the onset of relapse. The method of claim 6, wherein the supportive regimen further comprises treating the patient with at least one dose of about 150 mg to about 300 mg of an anti-IL-17 antibody at th
